Identifying and Validating Potential Biomarkers of Early Stage Lung Adenocarcinoma Diagnosis and Prognosis
BackgroundLung adenocarcinoma (LUAD) is the most common pathological type of lung cancer. At present, most patients with LUAD are diagnosed at an advanced stage, and the prognosis of advanced LUAD is poor. Hence, we aimed to identify novel biomarkers for the diagnosis and treatment of early stage LU...
Main Authors: | Yingji Chen, Longyu Jin, Zhibin Jiang, Suo Liu, Wei Feng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.644426/full |
Similar Items
-
Four long noncoding RNAs act as biomarkers in lung adenocarcinoma
by: Zhang Zhihui, et al.
Published: (2021-04-01) -
CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients
by: Yanwei Zhang, et al.
Published: (2020-06-01) -
Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics
by: Cheng Chen, et al.
Published: (2021-05-01) -
Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma
by: Xuanwen Bao, et al.
Published: (2020-05-01) -
Bioinformatics analysis of microarray data to identify the candidate biomarkers of lung adenocarcinoma
by: Tingting Guo, et al.
Published: (2019-07-01)